Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Mallinckrodt
Moodys
AstraZeneca
Medtronic

Last Updated: October 24, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 209310

See Plans and Pricing

« Back to Dashboard

NDA 209310 describes SINUVA, which is a drug marketed by Intersect Ent Inc and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug. Additional details are available on the SINUVA profile page.

The generic ingredient in SINUVA is mometasone furoate. There are thirty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.
Summary for 209310
Tradename:SINUVA
Applicant:Intersect Ent Inc
Ingredient:mometasone furoate
Patents:10
Formulation / Manufacturing:see details
Pharmacology for NDA: 209310
Medical Subject Heading (MeSH) Categories for 209310
Suppliers and Packaging for NDA: 209310
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310 NDA Intersect ENT, Inc. 10599-003 10599-003-01 1 POUCH in 1 CARTON (10599-003-01) > 1 IMPLANT in 1 POUCH

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:IMPLANT;IMPLANTATIONStrength1.35MG
Approval Date:Dec 8, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 8, 2020
Regulatory Exclusivity Use:NEW PRODUCT
Patent:  Start TrialPatent Expiration:Nov 29, 2026Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT
Patent:  Start TrialPatent Expiration:Mar 12, 2024Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
McKesson
AstraZeneca
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.